Article Per Year (5 Year)
p-Index From 2021 - 2026
1.503
P-Index
This Author published in this journals
All Journal Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Indonesian Journal of Urology Journal of Applied Nursing and Health Indonesian Journal of Cancer Indonesian Journal of Biomedicine and Clinical Sciences
Raden Danarto
Division Of Urology, Department Of Surgery, Faculty Of Medicine, Public Health And Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Veterinary

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
Statins and Survival in Castration-Resistant Prostate Cancer After Abiraterone or Enzalutamide: A Systematic Review Setiawan, Encep Ivan; Danarto, Raden
Indonesian Journal of Cancer Vol. 20 No. 2 (2026): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i2.1458

Abstract

Background: Prostate cancer is the second most commonly diagnosed cancer in men worldwide and a leading cause of cancer-related mortality. Castration-resistant prostate cancer (CRPC) develops despite androgen deprivation therapy (ADT), often after treatment with abiraterone or enzalutamide. Statins have shown potential anticancer effects through inhibition of HMG-CoA reductase and related signaling pathways. This systematic review evaluated whether statin use improves survival and disease outcomes in patients with CRPC previously treated with abiraterone or enzalutamide.Methods: A systematic search of PubMed, ProQuest, SAGE, and Europe PMC was conducted following PRISMA and Cochrane guidelines. Studies published within the last 10 years were included if they involved adults with CRPC receiving ADT or orchiectomy and compared statin users with non-users. Risk of bias was assessed using RoB 2.0 for randomized controlled trials (RCTs) and ROBINS-I for non-randomized studies. Primary outcomes were overall survival (OS), cancer-specific survival (CSS), and prostate-specific antigen (PSA) response.Results: Eight studies (two RCTs and six retrospective cohort studies) involving 35,401 patients were included. Most studies had a low to moderate risk of bias. Results were heterogeneous. Two of four studies reported significantly improved OS among statin users, while the remaining studies found no significant association. One study showed improved CSS, and two studies reported higher PSA response rates with statin use. However, these benefits were not consistently observed throughout all studies.Conclusion: Statin use may improve survival outcomes and PSA response in patients with CRPC. However, current evidence remains
Co-Authors Ahmad Zulfan Ahmad Zulfan Hendri Alharsya Franklyn Ruckle Andy Zulfiqqar Budiono, Nur Didik Setyo Heriyanto Ery Kus Dwianingsih Frannata, Lucky Indrawarman Soerohardjo Indrawarman Soeroharjo Indwiani Astuti Jundi, Abdur Rahman Faqih Al Mauny, Muhammad Puteh Muhammad Puteh Mauny Muhammad Puteh Mauny Prahara Yuri Prakoso, Ragil Unggul Risan, Muhammad Rudi Rafian Setiawan, Encep Ivan Sofia Mubarika Haryana Susanto, Gaeta Nurprimavera Yurisal Akhmad Dany Zulfikar Ali, Zulfikar